BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $11.50 million. The enterprise value is $7.03 million.

Market Cap	11.50M
Enterprise Value	7.03M

Important Dates

The last earnings date was Monday, March 31, 2025, before market open.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 1.31 billion shares outstanding. The number of shares has increased by 18.60% in one year.

Current Share Class	n/a
Shares Outstanding	1.31B
Shares Change (YoY)	+18.60%
Shares Change (QoQ)	+9.05%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.40
Forward PS	n/a
PB Ratio	0.85
P/TBV Ratio	3.82
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.76, with a Debt / Equity ratio of 1.12.

Current Ratio	1.76
Quick Ratio	1.53
Debt / Equity	1.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.13

Financial Efficiency

Return on equity (ROE) is -69.11% and return on invested capital (ROIC) is -45.48%.

Return on Equity (ROE)	-69.11%
Return on Assets (ROA)	-23.58%
Return on Invested Capital (ROIC)	-45.48%
Return on Capital Employed (ROCE)	-82.54%
Revenue Per Employee	$366,329
Profits Per Employee	-$116,722
Employee Count	79
Asset Turnover	0.56
Inventory Turnover	3.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -93.30% in the last 52 weeks. The beta is 0.93, so BioLineRx's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-93.30%
50-Day Moving Average	3.51
200-Day Moving Average	16.07
Relative Strength Index (RSI)	37.26
Average Volume (20 Days)	25,803

Short Selling Information

Short Interest	207,530
Short Previous Month	229,188
Short % of Shares Out	6.34%
Short % of Float	n/a
Short Ratio (days to cover)	3.87

Income Statement

In the last 12 months, BioLineRx had revenue of $28.94 million and -$9.22 million in losses. Loss per share was -$0.01.

Revenue	28.94M
Gross Profit	19.68M
Operating Income	-19.40M
Pretax Income	-49.15M
Net Income	-9.22M
EBITDA	-15.33M
EBIT	-19.40M
Loss Per Share	-$0.01

Full Income Statement

Balance Sheet

The company has $19.56 million in cash and $15.04 million in debt, giving a net cash position of $4.52 million or $0.00 per share.

Cash & Cash Equivalents	19.56M
Total Debt	15.04M
Net Cash	4.52M
Net Cash Per Share	$0.00
Equity (Book Value)	13.46M
Book Value Per Share	0.01
Working Capital	11.70M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$43.87 million and capital expenditures -$53,000, giving a free cash flow of -$43.93 million.

Operating Cash Flow	-43.87M
Capital Expenditures	-53,000
Free Cash Flow	-43.93M
FCF Per Share	-$0.03

Full Cash Flow Statement

Margins

Gross margin is 67.99%, with operating and profit margins of -67.03% and -31.86%.

Gross Margin	67.99%
Operating Margin	-67.03%
Pretax Margin	-31.86%
Profit Margin	-31.86%
EBITDA Margin	-52.98%
EBIT Margin	-67.03%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.60%
Shareholder Yield	-18.60%
Earnings Yield	-80.20%
FCF Yield	-382.06%

Analyst Forecast

The average price target for BioLineRx is $53.00, which is 1,715.07% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$53.00
Price Target Difference	1,715.07%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Jan 30, 2025
Split Type	Reverse
Split Ratio	0.025:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1